uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
9.75
-0.87 (-8.19%)
At close: Apr 3, 2025, 4:00 PM
9.74
-0.01 (-0.07%)
Pre-market: Apr 4, 2025, 9:18 AM EDT

Company Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.

The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.

Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease.

The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease.

It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering.

uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.
uniQure logo
Country Netherlands
Founded 1998
IPO Date Jun 20, 2007
Industry Biotechnology
Sector Healthcare
Employees 209
CEO Matthew Kapusta

Contact Details

Address:
Paasheuvelweg 25
Amsterdam, 1105 BP
Netherlands
Phone 31 20 240 6000
Website uniqure.com

Stock Details

Ticker Symbol QURE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001590560
CUSIP Number N90064101
ISIN Number NL0010696654
SIC Code 2834

Key Executives

Name Position
Matthew Craig Kapusta CPA Chief Executive Officer and Executive Director
Christian Klemt Chief Financial Officer, Principal Financial Officer and GM of Amsterdam Site
Richard Porter Ph.D. Chief Business and Scientific Officer
Dr. Jeannette Potts J.D., Ph.D. Chief Legal and Compliance Officer and Corporate Secretary
Prof. Hugo Katus Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Dr. Amin Abujoub Ph.D. Chief Technical Operations Officer
Dr. Tamara Tugal Ph.D., MBA Business Development Director
Erin Boyer Chief People and Culture Officer
Dr. Walid Abi-Saab M.D. Chief Medical Officer
Eileen Sawyer Vice President of Global Medical Affairs

Latest SEC Filings

Date Type Title
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Jan 8, 2025 8-K Current Report
Jan 8, 2025 424B5 Filing
Jan 7, 2025 424B5 Filing
Jan 7, 2025 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Dec 17, 2024 SCHEDULE 13G Filing
Dec 10, 2024 144 Filing
Dec 10, 2024 8-K Current Report